Could Cannabis Fruit Help Unlock a New Approach to IBS?

Cannabis research often focuses on familiar compounds such as THC and CBD. However, the cannabis plant contains many other substances that may affect the body in very different ways. A new study¹ investigating a traditional Chinese herbal formula offers an example of how much remains to be explored.

The researchers examined Tiaoqi Daozhi Decoction, an eight-herb formula used to treat constipation associated with what traditional Chinese medicine describes as liver depression and stagnant qi. One of its central ingredients is the fruit of Cannabis sativa, commonly associated with hemp seed in traditional medicine.

Using human gene-expression data, machine learning, molecular simulations, and experiments in rats, the researchers developed a possible explanation for how the complete formula could improve constipation-predominant irritable bowel syndrome. Their results also identified a cannabis-derived compound called hyndarin as one potentially important part of that process.

The findings do not show that cannabis can treat irritable bowel syndrome in people. They do, however, point toward an overlooked area of cannabis science: non-intoxicating compounds from cannabis fruit that may influence inflammation, communication between the gut and nervous system, and the movement of water through the intestines.

What Is Constipation-Predominant IBS?

Irritable bowel syndrome is a chronic condition that can cause abdominal pain and changes in bowel habits. Some patients mainly experience diarrhea, while others alternate between diarrhea and constipation. People with constipation-predominant IBS, also called IBS-C, usually experience hard stools, infrequent bowel movements, and difficulty passing stool.

IBS-C is not simply a matter of food moving too slowly. The condition can involve several overlapping systems. These include the immune system, intestinal nerves, the gut lining, water transport, emotional stress, and the microorganisms living in the digestive tract.

This complexity helps explain why a treatment that affects only one biological target may not work for every patient. The researchers behind the new study wanted to determine whether a multi-ingredient herbal formula could influence several connected processes at once.

Where Cannabis Enters the Study

Tiaoqi Daozhi Decoction contains eight herbal ingredients. These include Cyperi Rhizoma, Linderae Radix, Cannabis sativa fruit, bitter apricot seed, rose flower, Trichosanthes fruit, Curcuma rhizome, and mint.

Importantly, the cannabis ingredient was not THC-rich flower, an extract, or a conventional medical cannabis product. It was cannabis fruit used as one part of a larger traditional formula. The study therefore examined a very different side of the plant than most modern cannabis research.

The researchers initially identified 74 potentially active compounds across the eight ingredients. They then used databases and human intestinal gene-expression records to look for connections between those compounds and biological changes associated with IBS-C.

Three genes emerged as especially important: SELP, CETP, and BTK. All three were more active in intestinal tissue samples from people with IBS-C than in samples from healthy controls. The researchers proposed that these genes may contribute to inflammation, disrupted nerve signaling, and abnormal water transport in the colon.

A Cannabis Compound Becomes a Lead Candidate

The most direct cannabis-related finding involved hyndarin, which the researchers identified as a major active compound from Cannabis sativa fruit. Computer simulations indicated that hyndarin could fit into a protein called Bruton’s tyrosine kinase, or BTK.

BTK helps control the activity of immune cells, including mast cells. When mast cells become overactive, they can release inflammatory substances and an enzyme called tryptase. The researchers proposed that tryptase may break down vasoactive intestinal peptide, commonly shortened to VIP.

VIP is a signaling molecule that helps regulate intestinal muscles, nerves, and water transport. If excessive mast-cell activity reduces the amount of available VIP, communication within the digestive system may become less effective.

The proposed chain of events is relatively straightforward:

• Elevated BTK activity may contribute to excessive mast-cell activation.
• Activated mast cells may release more tryptase.
• Tryptase may break down VIP in the intestine.
• Lower VIP availability may weaken signals controlling intestinal movement and water transport.
• Hyndarin could potentially interfere with BTK and help preserve this signaling system.

In the molecular docking analysis, hyndarin produced a binding score of -8.447 kilocalories per mole with BTK. It was the strongest reported interaction in the study. A 100-nanosecond molecular dynamics simulation also suggested that the hyndarin and BTK complex remained structurally stable.

These results make hyndarin an interesting candidate for further research, but they do not prove that it blocks BTK inside a living animal or human. Computer simulations can show that an interaction appears physically possible. Direct laboratory experiments are still needed to confirm that the compound binds to the protein and changes its activity.

How the Complete Formula Performed

The researchers tested the complete decoction in rats with symptoms designed to resemble IBS-C. Compared with untreated animals in the disease model, rats receiving the formula showed improvements in several measures related to constipation.

The changes generally became stronger as the treatment dose increased. The formula also increased the activity of the VIP-PKA-AQP3 pathway in colon tissue.

This pathway can be understood as a communication chain. VIP delivers a signal. PKA passes that signal through the cell. AQP3 acts as a channel that helps control water movement across the intestinal lining. Problems anywhere along this chain could contribute to dry stool and slow intestinal movement.

The Bigger Insight Is Not About THC or CBD

The study is notable because it shifts attention away from cannabinoids. Hyndarin is not presented as an intoxicating compound, and the investigated ingredient was cannabis fruit rather than cannabinoid-rich flower.

This distinction could become increasingly important as cannabis research matures. The plant contains a much wider chemical library than the substances responsible for its best-known effects. Seeds, roots, leaves, and other tissues may contain compounds with completely different biological roles.

The study also suggests that some future cannabis-derived therapies may not act through the endocannabinoid system. Hyndarin was investigated for its possible interaction with BTK, an immune signaling protein. That creates a very different research path from studying how THC or CBD interacts with cannabinoid receptors.

Another important insight is that cannabis may sometimes be most useful as one component of a wider formulation. The researchers did not propose that cannabis fruit performed every function in the decoction. Different ingredients were linked to different targets, potentially allowing the formula to influence several parts of IBS-C biology at the same time.

That possibility is scientifically interesting, but it also creates a major challenge. When eight herbs are given together, it becomes difficult to determine how much each ingredient contributes. The apparent benefits could come from one compound, interactions among several compounds, or the formula as a whole.

Why the Findings Remain Preliminary

The evidence is not yet strong enough to support using cannabis fruit or hyndarin as an IBS-C treatment. The human portion of the study involved analysis of existing gene-expression datasets, not treating patients with the formula. The actual treatment experiments were conducted in rats, with five animals per group used for the primary functional measurements.

The study also did not directly test purified hyndarin in the animals. Rats received the complete eight-herb decoction. This means the improvements cannot be assigned specifically to the cannabis ingredient.

Researchers did not confirm that hyndarin physically binds to BTK in cells or suppresses its activity. They also did not use genetic modification or a separate BTK inhibitor to prove that changes in this protein caused the observed improvements.

Future studies will need to isolate the cannabis-derived compound, test it independently, confirm its direct biological targets, establish safe dosing, and determine whether the results can be reproduced in humans. Controlled clinical trials would then be required before any treatment claims could be justified.

A New Direction for Cannabis Research

This study does not establish cannabis as a treatment for IBS-C. Its more valuable contribution is identifying a possible research direction that extends beyond THC, CBD, and the cannabis flower.

Hyndarin may offer scientists a starting point for investigating how compounds from cannabis fruit interact with immune signaling and gut function. Even if the complete proposed mechanism changes with further testing, the work highlights how much of the cannabis plant’s chemistry remains poorly understood.

For patients, the findings should be viewed as an early scientific lead rather than practical medical guidance. For cannabis researchers, they offer something more substantial: a reminder that some of the plant’s most interesting future applications may come from compounds that have received very little attention so far.

References:

^{1. Huang, L., Xu, Y., Huang, Y., Yang, X., & Duan, M. (2026). Multi-omics and machine learning uncover anti-IBS-C mechanism of Tiaoqi Daozhi decoction via immune-neuro-epithelial remodeling and VIP-PKA-AQP3 axis activation. Journal of Radiation Research and Applied Sciences, 19, 102630. https://doi.org/10.1016/j.jrras.2026.102630}